Jpmorgan Chase & CO Stoke Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 19,964 shares of STOK stock, worth $166,300. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,964
Previous 15,452
29.2%
Holding current value
$166,300
Previous $189,000
16.4%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding STOK
# of Institutions
136Shares Held
57.3MCall Options Held
5.7KPut Options Held
24.4K-
Skorpios Trust6.91MShares$57.5 Million99.8% of portfolio
-
Black Rock Inc. New York, NY5.41MShares$45.1 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR5.19MShares$43.2 Million22.22% of portfolio
-
Rtw Investments, LP New York, NY5.12MShares$42.7 Million0.92% of portfolio
-
Baker Bros. Advisors LP New York, NY4.63MShares$38.6 Million0.57% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $328M
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...